Structure Therapeutics Reports $144.8 Million Q3 Net Loss and $1.2 Billion Cash
The company reported a third-quarter 2026 net loss of $144.8 million and $1.2 billion in cash, cash equivalents and short-term investments as of September 30. Research and development expenses rose to $134.6 million from $59.0 million a year earlier.
Structure Therapeutics reported a third-quarter 2026 net loss of $144.8 million and $1.2 billion in cash, cash equivalents and short-term investments as of September 30. Research and development expenses rose to $134.6 million from $59.0 million a year earlier. The company said its cash is expected…